Engineered trimeric CD70 proteins and uses thereof
AssigneeFred Hutchinson Cancer Center
InventorsCarla A. Jaeger, Colin E. Correnti, Stanley R. Riddell
Life of this patent
Estimating the term…
Abstract
Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; selective expansion of nave and memory T cell subsets; longer persistence in vivo following administration to a subject; and improved therapeutic effect. Use of the proteins as therapeutics provide anti-cancer and anti-viral effects. The proteins can also be used as agonistic cell culture reagents in in vitro uses.
Claims18
An ex vivo method of manufacturing a T cell population for administration to a subject, the method comprising:
- obtaining a population of T cells;
- culturing the population of T cells within a culture media comprising:
- a CD3 stimulating molecule and an Fc-dimerized protein at a concentration sufficient to increase T cell activation, wherein the Fc-dimerized protein has two copies of the single chain protein sequence as set forth in SEQ ID NO:
- 5 or a sequence having at least 95% sequence identity to the sequence as set forth in SEQ ID NO:
- 5 to create an activated T cell population;
- culturing the activated T cell population within a culture media lacking the CD3 stimulating molecule;
- and
- formulating the expanded T cell population into a pharmaceutically acceptable carrier in a therapeutically effective amount,
- thereby ex vivo manufacturing the T cell population for administration to the subject.
Dependencies are inferred from the claim text.